Garon EB, Hellmann MD, Costa EC, et al. Five-year long-term overall survival for patients with advanced NSCLC treated with pembrolizumab: Results from KEYNOTE-001. ASCO Annual Meeting 2019, abstract LBA9015.
PARP-remmers: een nieuw tijdperk in de behandeling van (recidiverende) ovariumkanker
aug 2020 | Gynaecologische oncologie